

CURRICULUM VITAE FOR ACADEMIC PROMOTION
The Johns Hopkins University School of Medicine

Antonio C. Wolff, M.D.

April 15, 2011

DEMOGRAPHIC INFORMATION

Current Appointment

2005-present Associate Professor, Department of Oncology, Johns Hopkins

Personal Data

Office Address

Business Address Breast Cancer Program
Department of Oncology
The Johns Hopkins Kimmel Comprehensive Cancer Center
1650 Orleans Street, CRB1-189
Baltimore, MD 21231-1000
Phone: 410 614-4192
Fax: 410 614-4073
E-mail: awolff@jhmi.edu

Education and Training (in chronological order)

Doctoral/Graduate

1986 M.D., Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
(ECFMG Certificate #413-744-4)

Postdoctoral

1987 – 1988 Resident, Internal Medicine, Universidade Federal do Rio de Janeiro, Brazil
1988 – 1989 Intern, Internal Medicine, Good Samaritan Hospital, Baltimore, MD
1989 – 1990 Resident, Internal Medicine, Good Samaritan Hospital, Baltimore, MD
1990 – 1991 Resident, Internal Medicine, Mount Sinai Medical Center, New York, NY
1991 – 1992 Post-Doctoral Fellow, Hematology/Oncology, Washington University, St. Louis, MO
1992 – 1995 Post-Doctoral Fellow, Medical Oncology, Johns Hopkins University, Baltimore, MD
(1993-1995, lab training, PI [Michael B. Kastan, M.D., Ph.D.] & Biostatistics Courses
[for credit], JH Bloomberg School of Public Health, Baltimore, MD)

Professional Experience

1995 – 1998 Assistant Professor, Medicine (Hematology/Oncology), Emory University, Atlanta, GA
1997 – 1998 Chief, Division of Hematology Oncology, Atlanta V.A. Medical Center, Atlanta, GA
1998 – 2005 Assistant Professor, Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
2001 – 2005 Co-Director, Medical Oncology Fellowship Program, Johns Hopkins University School of Medicine, Baltimore, MD
2005 – present Associate Professor, Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

RESEARCH ACTIVITIES

Peer Reviewed Original Science Publications

1. Canman CE*, **Wolff AC***, Chen C-Y, Fornace Jr AJ, Kastan MB. The p53-dependent G₁ cell cycle checkpoint pathway and Ataxia-Telangiectasia. *Cancer Res.* 1994; 54:5054-58. * CEC and ACW contributed equally for this work (PMID 7923116)
2. **Wolff AC**, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH. Phase II Study of Ifosfamide, Carboplatin, and Oral Etoposide Chemotherapy for Extensive-Disease Small Cell Lung Cancer: An Eastern Cooperative Oncology Group Pilot Study. *J Clin Oncol.* 1995; 13(7):1615-1622 (PMID 7602350)
3. Sparano JA, Hu P, Rao RM, Falkson CI, **Wolff AC**, Wood WC. Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study. *J Clin Oncol.* 1999; 17(12):3828-3834. (PMID 10577856)
4. Sparano JA, Malik U, Radjev L, Sarta C, Hopkins C, Hopkins U, **Wolff AC**. Phase I trial of pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer. *J Clin Oncol.* 2001; 19(12):3117-3125. (PMID 11408509)
5. Bradley MO, Swindell CS, Anthony FH, Witman PA, Devanesan P, Webb NL, Baker SD, **Wolff AC**, Donehower RC. Tumor targeting by conjugation of DHA to paclitaxel. *J Control Release.* 2001; 74(1-3): 233-236. (PMID 11489499)
6. Sparreboom A, **Wolff AC**, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower, RC, Baker SD. Disposition of Docosahexaenoic Acid-Paclitaxel, a Novel Taxane, in Blood: In Vitro and Clinical Pharmacokinetic Studies. *Clin Cancer Res.* 2003; 9:151-159. (PMID 12538463)
7. **Wolff AC**, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. *Clin Cancer Res.* 2003; 9:3589-3597. (PMID 14506145)
8. Zhao M, Zabelina Y, Rudek MA, **Wolff AC**, Baker SD. A rapid and sensitive method for determination of Dimethyl Benzoylphenyl Urea in human plasma by using LC/MS/MS. *J Pharm Biomed Anal.* 2003; 33:725-733. (PMID 14623599)
9. **Wolff AC**, Armstrong DK, Fetting JH, Carducci, MK, Riley CD, Bender JF, Casero Jr RA, Davidson NE. A Phase II Study of the Polyamine Analogue N1, N11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer. *Clin Cancer Res.* 2003; 9:5922-5928. (PMID 14676116)
10. Miller KD, Saphner TJ, Waterhouse DM, Chen T-T, Rush-Taylor A, Sparano JA, **Wolff AC**, Cobleigh MA, Galbraith S, Sledge GW. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. *Clin Cancer Res.* 2004; 10:1976-1983. (PMID 15041714)
11. Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR, **Wolff AC**, Sparreboom A, Carducci MA. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. *Clin Cancer Res.* 2004; 10:1976-1983. (PMID 15041715)
12. Rudek MA, Sparreboom A, Garrett-Mayer E, Armstrong DK, **Wolff AC**, Verweij J, Baker SD. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. *Eur J Cancer.* 2004; 40:1170-8. (PMID 15110880)
13. Rudek MA, Zabelina Y, Zhao M, **Wolff AC**, Baker SD. A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. *Biomed Chromatogr.* 2004; 18: 282-287. (PMID 15236435)
14. Winer, EP, Hudis, C, Burstein, HJ, **Wolff AC**, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. *J Clin Oncol.* 2005; 23:619-629. (PMID 15545664)
15. Jacobs MA, Ouwerkerk R, **Wolff AC**, Stearns V, Bottomley PA, Barker PB, Argani P, Khouri N, Davidson NE, Bhujwala ZM, Bluemke DA. Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. *Technol Cancer Res Treat.* 2004; 3:543-550. (PMID 15560711)
16. Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K, **Wolff A**. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. *Hum Gene Ther.* 2004;15:313-37. (PMID 15018740)
17. Lyman GH, Giuliano AE, Somerfield MR, Benson III AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody III HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, **Wolff AC**, Winer EP. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. *J Clin Oncol.* 2005; 23:7703-7720. (PMID 16157938)
18. Rudek MA, Zhao M, He P, Zabelina Y, Jin R, Messersmith WA, **Wolff AC**, Baker SD. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate Dimethyl Benzoylphenylurea (BPU) and its 5 metabolites in human plasma and urine for clinical pharmacology studies. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2005; 828:41-54 (PMID 16253576)

19. **Wolff AC**, O'Neill A, Kennedy MJ, Stewart JA, Gradishar WJ, Lord RS 3rd, Davidson NE, Wood WC. Single Agent Topotecan as First-Line Chemotherapy in Women with Metastatic Breast Cancer: Final Results of Eastern Cooperative Oncology Group Trial E8193. *Clin Breast Cancer*. 2005; 6:334-339. (PMID 16277884)
20. Rudek MA, Zhao M, Smith NF, Robey RW, He P, Hallur G, Khan S, Hidalgo M, Jimeno A, Colevas AD, Messersmith WA, **Wolff AC**, Baker SD. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea (BPU), a novel oral tubulin-interactive agent. *Clin Cancer Res*. 2005; 11:8503-8511. (PMID 16322314)
21. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demitri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield M, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, **Wolff AC**. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. *J Clin Oncol*. 2006; 24: 3187-3205. (PMID 16682719)
22. **Wolff AC**, Jones RJ, Davidson NE, Jeter S, Stearns V. Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy with Pegfilgrastim Support. *J Clin Oncol*. 2006; 24:2392-2394. (PMID 16710041)
23. Khatcheressian JL, **Wolff AC**, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR, Davidson NE. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-up and Management Guideline in the Adjuvant Setting. *J Clin Oncol*. 2006; 24(31):5091-5097. (PMID 17033037)
24. Messersmith WA, Rudek MA, Baker SD, Zhao M, Zabelina Y, Collins C, Colevas AD, Donehower RC, Carducci MA, **Wolff AC**. Phase I Study of Continuous Weekly Dosing of Dimethylamino Benzoylphenylurea (BPU) in Patients with Solid Tumors. *Eur J Cancer*. 2007; 43:78-86. (PMID 17084620)
25. **Wolff AC**, Hammond MEH, Schwartz JN, Hagerty K, Allred DC, Cote R, Dowsett M, Fitzgibbons PL, Gutman S, Hanna W, Keegan P, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube S, Tubbs R, Vance GH, van de Vijver M, Wheeler T, Yost J, Hayes DF. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for HER2 Testing in Breast Cancer, *J Clin Oncol*, 25: 118-145, 2007. (PMID 17159189)
26. **Wolff AC**, Hammond MEH, Schwartz JN, Hagerty K, Allred DC, Cote R, Dowsett M, Fitzgibbons PL, Gutman S, Hanna W, Keegan P, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube S, Tubbs R, Vance GH, van de Vijver M, Wheeler T, Yost J, Hayes DF. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for HER2 Testing in Breast Cancer *Arch Pathol Lab Med*. 2007;131(1):18. (PMID 19548375)
27. Ouwerkerk R, Jacobs MA, Macura KJ, **Wolff AC**, Stearns V, Mezban SD, Khouri NF, Bluemke DA, Bottomley PA. Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive (23)Na MRI. *Breast Cancer Res Treat*. 2007;106:151-60. (PMID 17260093)
28. Snyder CF, Dy SM, Hendricks DE, Brahmer JR, Carducci MA, **Wolff AC**, Wu AW. Asking the Right Questions: Investigating Needs Assessments and Health-Related Quality of Life Questionnaires for Use in Oncology Clinical Practice. *Supportive Care in Cancer*. 2007;15:1075-85. (PMID 17318591)
29. Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, **Wolff AC**, Ingle JN, Chew H K, Elias AD, Livingston RB, Martino S. Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. *J Clin Oncol*. 2007;25:1677-1682. (PMID 17404368)
30. Sparreboom A, **Wolff AC**, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. *J Clin Oncol* 2007;25:4707-13. (PMID 17947717)
31. Marchionni L, Wilson RF, Marinopoulos SS, **Wolff AC**, Parmigiani G, Bass EB, Goodman SN. Impact of gene expression profiling tests on breast cancer outcomes. *Evid Rep Technol Assess (Full Rep)* (160, AHRQ Publication No. 08-E002). 2008:1-105. (PMID 20629480)
32. Marchionni L, Wilson RF, **Wolff AC**, Marinopoulos S, Parmigiani G, Bass EB, and Goodman SN. Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer. *Annals Int Med* 2008;148:358-69. (PMID 18252678)
33. **Wolff AC**, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. *J Clin Oncol*. 2008; 26: 806-13. (PMID 18258990)
34. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, **Wolff AC**, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. A phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol*. 2008;26:1810-6. (PMID 18347007)
35. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, **Wolff AC**, Sledge Jr GW, Wood WC, Davidson NE, Weekly paclitaxel improves survival in lymph node positive and high risk node negative operable breast cancer. N

- Engl J Med. 2008;358:1663-71. (PMID 18420499)
36. Snyder CF, Garrett-Mayer E, Brahmer JR, Carducci MA, Pili R, Stearns V, **Wolff AC**, Dy SM, Wu AW. Symptoms, Supportive Care Needs, and Function in Cancer Patients: How Are They Related? *Quality of Life Research*. 2008;17:665-77. (PMID 18493865)
 37. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, **Wolff AC**, Carducci MA, Sparreboom A. Pharmacogenetic Pathway Analysis of Docetaxel Elimination. *Clin Pharmacol Ther*. 2009;85:155-63. (PMID 18509327)
 38. Partridge AH, **Wolff AC**, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. The impact of sharing results of a randomized breast cancer clinical trial with study participants. *Breast Cancer Res Treat*. 2009;15:123-9 (PMID 18543100)
 39. Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL, **Wolff AC**, Brancati FL. Increased Long-term, All-cause Mortality in Cancer Patients with Pre-existing Diabetes Mellitus: A Systematic Review and Meta-Analysis. *JAMA*. 2008;300:2754-2764. (PMID 19088353)
 40. Snyder CF, Frick KD, Peairs KS, Kantsiper ME, Herbert RJ, Blackford AL, **Wolff AC**, Earle CC. Comparing Care for Breast Cancer Survivors to Non-Cancer Controls: A Five-Year Longitudinal Study. *J Gen Intern Med*. 2009; 24:469-74, 2009 (PMID 19156470)
 41. Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, **Wolff AC**, and Earle CC. Prevention, Screening, and Surveillance Care for Breast Cancer Survivors Compared With Controls: Changes from 1998 to 2002. *J Clin Oncol*. 2009;27:1054-61. (PMID 19164212)
 42. Zellars R, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens L, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, **Wolff AC**. Partial Breast Irradiation and Concurrent dose-dense Doxorubicin and Cyclophosphamide. *J Clin Oncol*. 2009;27:2816-22 (PMID 19332718)
 43. Muss H, Berry D, Cirincione C, Theodoulou M, Mauer A, Kornblith A, Partridge A, Dressler L, Cohen H, Becker H, Norton L, Kartcheske P, Wheeler J, Perez E, **Wolff AC**, Gralow J, Burstein H, Mahmood A, Parker B, Hudis C, Winer EP, for the Cancer and Leukemia Group B. Adjuvant Chemotherapy with Standard Regimens is Superior to Capecitabine in Older Women. *N Engl J Med*. 2009;360:2055-65. Erratum in: *N Engl J Med*. 2009;361:1714. Magrinat, Gutav [corrected to Magrinat, Gustav]. (PMID 19439741)
 44. Balmanoukian A, Zhang Z, Jeter S, Slater S, Armstrong DK, Emens LA, Fetting JH, **Wolff AC**, Davidson NE, Jacobs L, Lange J, Tsangaris TN, Zellars R, Gabrielson E, Stearns V. African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. *J Clin Oncol*. 2009;27:e35-7; author reply e38-9 (PMID 19564528)
 45. Snyder CF, Garrett-Mayer E, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, **Wolff AC**, Dy SM, Wu AW. Concordance of cancer patients' function, symptoms, and supportive care needs. *Qual Life Res*. 2009;18:991-8 (PMID 19657724)
 46. Stein KB, Snyder CF, Barone BB, Yeh HC, Peairs KS, Derr RL, **Wolff AC**, Brancati FL. Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Dig Dis Sci*. 2010;55:1839-51. (PMID 19731028)
 47. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, **Wolff AC**, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. *J Clin Oncol*. 2009;27:5911-8 (PMID 19805669).
 48. Kantsiper M, McDonald EL, Geller G, Shockney L, Snyder C, **Wolff AC**. Transitioning to Breast Cancer Survivorship: Perspectives of Patients, Cancer Specialists, and Primary Care Providers. *J Gen Intern Med*. 2009;24(Supp 2):S459 (PMID 19838851)
 49. Chumsri S, Jeter S, Jacobs LK, Nassar H, Armstrong DK, Emens LA, Fetting JH, Lange JR, Riley C, Tsangaris TN, **Wolff AC**, Zellars R, Zhang Z, Stearns V. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. *Clin Breast Cancer*. 2010;10:40-5 (PMID 20133257)
 50. Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh HC, Derr RL, **Wolff AC**, Carducci MA, Brancati FL. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. *Prostate Cancer Prostatic Dis*. 2010;13:58-64 (PMID 20145631)
 51. **Wolff AC**, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, Sparano JA, Davidson NE. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. *Breast Cancer Res Treat*. 2010;121:111-20. (PMID 20333545)

52. Snyder CF, Blackford AL, Brahmer, JR, Carducci, MA, Pili R, Stearns V, **Wolff AC**, Dy SM, and Wu AW. Need Assessments Identify Scores on HRQOL Questionnaires that Represent Problems for Patients: An Illustration with the Supportive Care Needs Survey and the QLQ-C30. *Qual Life Res.* 2010;19:837-45 (PMID 20340048)
53. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, **Wolff AC**, and Brancati FL. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. *Diabetes Care.* 2010;33:931-9 (PMID 20351229)
54. Partridge AH, Archer L, Kornblith A, Gralow J, Greiner D, Perez E, **Wolff AC**, Xiaofei W, Kastrissios H, Berry D, Hudis C, Winer E and Muss H. Adherence and Persistence with Oral Adjuvant Chemotherapy in Older Women with Early Stage Breast Cancer in CALGB (Adherence Companion Study 60104). *J Clin Oncol.* 2010;28:2418-22 (PMID 20368559)
55. Hammond EH, Hayes DF, Dowsett M, Allred DC, Hagerty K, Badve S, Fitzgibbons PL, Francis G, Goldstein N, Hayes M, Hicks D, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep F, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, **Wolff AC**. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen/Progesterone Receptors in Breast Cancer. *J Clin Oncol.* 2010;28:2784-95. Erratum in: *J Clin Oncol.* 2010;28:3543 (PMID 20404251)
56. Hammond EH, Hayes DF, Dowsett M, Allred DC, Hagerty K, Badve S, Fitzgibbons PL, Francis G, Goldstein N, Hayes M, Hicks D, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep F, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, **Wolff AC**. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen/Progesterone Receptors in Breast Cancer. *Arch Pathol Lab Med.* 2010;134:907-22 abridged version (PMID 20524868)
57. Chavez-MacGregor M, Litton J, Chen H, Giordano SH, Hudis CA, **Wolff AC**, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathological complete response in breast cancer patients receiving anthracycline and taxane-based neoadjuvant chemotherapy: Evaluating the effect of race/ethnicity. *Cancer.* 2010;116:4168-77 (PMID 20564153)
58. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, **Wolff AC**. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *Arch Pathol Lab Med.* 2010;134:e48-72 unabridged version (PMID 20586616)
59. Jacobs MA, Stearns V, **Wolff AC**, Macura K, Khouri N, Tsangaris TN, Davidson NE, Bhujwala Z, Bluemke DA, Ouwkerk R. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. *Acad Radiol.* 2010;17:1477-85 (PMID 20863721)
60. Peairs KS, Barone BB, Snyder CF, Yeh H-C, Derr RL, Brancati FL, **Wolff AC**. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. *J Clin Oncol.* 2011;29:40-6 (PMID 21115865)
61. Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, **Wolff AC**. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. *Breast Cancer Res Treat.* 2011 May;127(1):153-162. Epub 2011 Feb 25 (PMID 21350820)
62. Dy SM, Asch SM, Lorenz, KA, Weeks K, Sharma RK, **Wolff AC**, Malin, JL. Quality of End-of-Life Care for Patients with Advanced Cancer in an Academic Medical Center. *J Palliat Med.* 2011 Apr;14(4):451-7. Epub 2011 Mar 10 (PMID 21391819)
63. Jacobs MA, Ouwkerk R, **Wolff AC**, Gabrielson E, Warzecha H, Jeter S, Bluemke DA, Wahl R, Stearns V. Monitoring of neoadjuvant chemotherapy using multiparametric, (²³Na) sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. *Breast Cancer Res Treat.* 2011 Apr 1. [Epub ahead of print] (PMID 21455671)
64. Hammond EH, Hayes DF, **Wolff AC**. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer. *J Clin Oncol* 2011 (*in press*, e-publication date April 18, 2011)

Extramural Sponsorship

CURRENT

- 4/1/00 – 3/31/11 Enhancing Accrual of Women with Breast Cancer to NCI-Sponsored Clinical Trials at Johns Hopkins
90033023
Susan G. Komen for the Cure Foundation- Maryland Project CRAFT (annual competitive application)
\$75,000
Principal Investigator; 0.12 calendar months; The major goal of this project is to increase the accrual of women with breast cancer to NCI-sponsored clinical trials at Johns Hopkins.
- 4/1/11– 3/31/14 Molecular Marker Signature Prognostic of Metastatic Disease in Node-Negative ER-Negative Breast Cancer with No Systemic Therapy
KG110094
Susan G. Komen for the Cure Research Program
\$559,353
PI: C Umbricht
Co-Investigator; 0.12 calendar months; The major goal of this project are to identify molecular markers (RNA expression and methylation) that have differential prognostic utility in early stage breast cancer patients with ER-negative disease.
- 5/1/04 – 4/30/11 Eastern Cooperative Oncology Group (ECOG)
U10 CA016116-31
NCI
\$354,967
PI: A Forastiere
Co-Investigator; 0.12 calendar months; The major goals of this project are to develop and implement clinical research protocols and correlative laboratory studies within ECOG.
- 10/1/05 – 9/30/11 Partnership between the Translational Breast Cancer Research Consortium and the Breast Cancer Research Foundation
90021105
Breast Cancer Research Foundation – TBCRC
\$1,250,000
Principal Investigator; 1.2 calendar months; The major goal of this project is to establish a partnership between the Translational Breast Cancer Research Consortium and the Breast Cancer Research Foundation to support a clinical research network across 16 academic breast cancer programs.
- 7/1/06 – 6/30/11 Partnership between Translational Breast Cancer Research Consortium and Avon Foundation
90028544
Avon Foundation – TBCRC
\$500,000
Principal Investigator; 1.2 calendar months; The major goal of this project is to establish a partnership between the Translational Breast Cancer Research Consortium and the Avon Foundation to support a clinical research network across 16 academic breast cancer programs.
- 3/5/08 – 5/31/13 Partnership between Translational Breast Cancer Research Consortium and Susan G. Komen for the Cure Foundation
K90033529
Susan G. Komen for the Cure – TBCRC
\$3,750,000
Principal Investigator; 1.2 calendar months; The major goal of this project is to establish a partnership between the Translational Breast Cancer Research Consortium and the Susan G. Komen for the Cure Foundation to support a clinical research network across 16 academic breast cancer programs.

- 4/1/08 – 3/31/12
A Survivorship Program for Breast Cancer: A Transition for Patients and Providers
90033368
Susan G. Komen for the Cure Maryland
\$187,000
Principal Investigator; 1.2 calendar months; The major goal of this project is to establish breast cancer follow-up care strategies for survivors and their health care providers and a comprehensive clinical and educational services model adaptable for use elsewhere.
- 4/1/09 – 3/31/11
Phase II Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2 Positive Breast Cancer
90034357
Genentech
\$100,000
Principal Investigator, 0.12 calendar months; The purpose of this study is to test the efficacy of a non-anthracycline regimen in lower-risk HER2 positive breast cancer.
- 4/1/09 – 3/31/11
A Phase II, Single-Arm, Open Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients with HER2-Positive Metastatic Breast Cancer
TDM43749
Genentech
\$100,000
Site Principal Investigator; 1.2 calendar months; The purpose of this study is to test the single-agent activity of T-DM1 in patients with HER2-positive refractory breast cancer in preparation for an FDA new Biologics License Application.
- 5/1/09 – 4/30/11
NCI Clinical Investigator Team Leadership Award
5P30 CA006973
NIH/NCI
\$49,694
CCSG PI – WG Nelson
Project Principal Investigator; 1.44 calendar months; This administrative supplement award is designed to support, acknowledge, and recognize outstanding clinical investigators whose participation and activities promote successful clinical research programs and to promote retention of clinical investigators in an academic career in clinical research.
- 6/1/09 – 12/31/10
Breast Cancer Outcomes Database
90038593
National Comprehensive Cancer Network
\$50,000
Principal Investigator; 0.12 calendar months; The purpose of this grant is to fund prospective database efforts in early stage breast cancer.
- 7/1/09-6/30/11
Serum DNA Methylation as a Tumor Marker
01-2009-031
Avon Foundation, Avon Breast Center of Excellence
\$750,000
PI, S. Sukumar
Co-Investigator; 1.2 calendar months; The purpose of this grant is to optimize the analytical component of a QM-MSP assay in peripheral blood.
- 8/1/09 – 7/31/11
Feasibility and Value of a Website for Assessing Patient Reported Outcomes
R21 CA134805-01A1
NIH/NCI
\$150,000
PI, CF Snyder/A Wu
Co-Investigator; 0.36 calendar months; The purpose of this study is to assess the use, usefulness, and acceptability of a website designed to collect patient-reported outcomes from cancer outpatients and link the data with the electronic medical record.

- 7/1/10 – 6/30/13 Comorbid Conditions in Cancer Survivors: Costs and Quality of Care
1R01CA149616-01A1
NIH
\$249,690
PI, KD Frick/CS Snyder
Co-Investigator; 0.24 calendar months; The purpose of this study is to use the SEER-Medicare dataset to compare the quality of care for comorbid conditions requiring acute interventions between cancer survivors and non-cancer controls, the rates of avoidable outcomes, and the association between quality indicators and costs.
- 9/30/00 – 9/29/11 Specialized Program in Research Excellence (SPORE in Breast Cancer)
P50 CA88843
NIH/NCI
\$250,000
PI, S. Sukumar
Co-Investigator; 1.2 calendar months; The overall goal of this proposal is to identify major molecular alterations in carcinoma of the breast by microarray analysis of all stages of tumor development, and develop markers for early detection.
- 7/1/10 – 6/30/12 Johns Hopkins Breast Cancer Program Longitudinal Repository
SAC110053
Susan G. Komen for the Cure Foundation
\$62,500
Principal Investigator; 0.12 calendar months; The purpose of this grant is to fund prospective database efforts in early stage breast cancer.
- PENDING** *none*
- PREVIOUS**
- 9/22/95 – 2/28/08 Phase I Clinical Trials of Anticancer Agents
UO1 CA70095
NIH-NCI
\$1,639,126
PI, MA Carducci
Co-Investigator, 0.48 calendar months; The purpose of this grant was to support early phase clinical trials in oncology under the UO1 mechanism.
- 3/1/98 – 2/29/03 North Carolina and Georgia Genetics Network Center
CA-97-004
Cancer Genetics Network
Information not available
PI, JD Iglehart
Co-Investigator until 06/30/1998; 0.6 calendar months; The purpose of this grant was to establish a cross-institution high-risk breast cancer genetics counseling and testing network.
- 4/1/99 – 9/30/00 Phase I Pilot Study of Marimastat Plus Docetaxel and Doxorubicin in Women with Advanced Breast Cancer.
99112806
Rhône Poulenc
\$252,453
Principal Investigator, 1.2 calendar months; The purpose of this grant was to explore the combination of the three drugs for possible subsequent development in the adjuvant setting.
- 9/30/00 – 7/31/03 A Religious Intervention in Black Women with Breast Cancer (P.I. – Diane Becker).
P50-AT00437
NCCAM – NIH
\$936,430
PI, A Dobs/ D Becker
Co-investigator, 0.6 calendar months; The purpose of this specific project in a larger program project grant was to examine the biologic effects on immunologic parameters in breast cancer patients.

- 4/13/01 – 3/31/02 A Multicenter Open-Label, Phase III Trial of rhuMAb VEGF in combination with Capecitabine
Chemotherapy
01051421
Genentech Inc.
\$161,844
Institutional Principal Investigator, 1.2 calendar months; The purpose of this trial was to conduct the first randomized trial of bevacizumab as second-line therapy preferentially in patients with HER2-negative metastatic breast cancer.
- 1/1/02 – 6/30/03 A Phase II, Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women with Stage 1c-IIIa Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy.
01051419
Bristol-Meyers Squibb
\$137,620
Institutional Principal Investigator; 2.4 calendar months; The purpose of this study was to test the safety of the matrix metalloproteinase inhibitor BMS-275291 in the adjuvant setting prior to launching a definitive randomized trial testing its efficacy.
- 5/1/03 – 4/30/05 Avon Breast Cancer Crusade Breast Cancer Research and Care Program Network
304-2259
Avon Breast Cancer Research
\$9,271,800
PI, NE Davidson
Co-Investigator; 1.2 calendar months; The purpose of this specific project in this grant was to fund a research nurse and study coordinator to support clinical research activities in the Breast Cancer Program.
- 5/15/03 – 4/30/05 Avon/NCI Partners for Progress Project – Phase I Study of Docetaxel/ST1571 in Breast Cancer
3 P30 CA06973-41S1
NIH – Regional Oncology Research Center
\$20,698,763
CCSG PI – MD Abeloff
Project PI; 2.4 calendar months; The purpose of this trial was to investigate pharmacokinetics and safety parameters of combining a taxane drug with the small molecule tyrosine kinase inhibitor imatinib.
- 7/1/03 – 6/30/07 Quantative ²³Na MRI of Breast Cancer
PAR-01-101 Development of novel technologies for In Vivo Imaging R21/R33
R21 CA095907
NCI
\$195,303
PI, R Ouwerkerk
Co-Investigator, 0.36 calendar months; The purpose of this collaborative imaging grant with the Department of Radiology at Johns Hopkins was to develop novel MRI imaging modalities using ²³-Sodium parameters in breast cancer.
- 8/1/03 – 7/31/08 JHU In Vivo Cellular and Molecular Imaging Center (JHU ICMIC)
1P50 CA 103175
NIH
\$6,341,041
PI, Z Bhujwala
Co-Investigator, 0.12 calendar months; The vision of this grant was to combine state-of-the-art imaging capabilities with powerful molecular biology techniques to define strategies with 'intent to cure' and to create a center consisting of a multidisciplinary group of premier individuals with diverse skills focused on translating molecular capabilities into imaging possibilities with the single purpose of understanding and curing cancer.
- 9/15/04 – 9/14/08 Evaluating Patient Information Prescriptions
R01 LM008143
NIH – RO1
\$669,712
PI, N Roderer
Co-Investigator, 0.6 calendar months; The purpose of this grant was to evaluate whether provision of prescribed information services (IRx) can improve patient satisfaction with information services.

- 10/1/04 – 9/30/05 A Phase II Study of SU011248 in Anthracycline- and Taxane-Resistant Metastatic Breast Cancer
A6181002
Pfizer
\$66,235
Institutional Principal Investigator, 0.6 calendar months; The purpose of this trial was to evaluate the single agent activity of the small molecule tyrosine kinase inhibitor sunitinib in refractory metastatic breast cancer.
- 2/1/05 – 1/31/06 A Phase III Randomized, Placebo controlled, Double Blind Study of Oral Letrozole ± CCI-779 as First-Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer
CCI-779
Wyeth
\$36,361
Institutional Principal Investigator, 1.2 calendar months; The purpose of this study was to conduct an efficacy randomized phase III study that could provide data for an FDA new drug application. Dr. Wolff is lead author of the manuscript soon to be submitted for publication.
- 4/1/05 – 3/31/08 Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
XEL-429
Roche
\$286,237
Principal Investigator, 0.6 calendar months; The purpose of this study was to test the efficacy and measure pharmacokinetic parameters of a capecitabine schedule using fixed starting doses in metastatic breast cancer.
- 5/1/05 – 4/30/07 Optimizing Oral Chemotherapy in Breast Cancer Using Fixed Dose Schedules: The Identification of Predictive Markers of Response and Toxicity to Capecitabine
BCTR0504444
Susan G. Komen for the Cure Foundation
\$200,000
Principal Investigator, 1.2 calendar months; The purpose of this study was to test the efficacy and measure pharmacokinetic parameters of a capecitabine schedule using fixed starting doses in metastatic breast cancer.
- 7/1/05 – 6/30/07 Avon/NCI Partners for Progress Project – DNA Methylation in Serum as a Predictive Marker in Metastatic Breast Cancer
P30 CA06973
NIH – Regional Oncology Research Center
\$20,698,763
PI: MD Abeloff
Project Principal Investigator, 2.4 calendar months; The purpose of this grant was to conduct a blood collection trial in metastatic breast cancer to explore the role of an assay of DNA methylation in blood as a predictor/prognostic marker.

Research Program Building/Leadership

- 04/2000 – ongoing Breast Cancer Clinical Research Program
In April 2000, I established the first disease-specific clinical research infrastructure in the Division of Medical Oncology of the Department of Oncology, and have since then identified and secured continuous external infrastructure-directed funds to partially support these activities. Our research staff of research coordinators, research nurses, and a program coordinator has since expanded. Since Oct 2002, I have shared this leadership role with Dr. Vered Stearns and co-lead the day-to-day operations and strategic decisions related to medical oncology clinical research activities in our Program.
- 05/2006 – ongoing Executive Officer, Translational Breast Cancer Research Consortium (www.tbcr.org)
- 09/2006 – ongoing Co-chair, Cancer Outcomes & Health Services Interest Group
In 2006, I co-established the CO&HSR Interest Group with Dr. Claire Snyder to bring together faculty members and trainees across our Schools of Medicine, Public Health, and Nursing who share common interests on the topic and foster collaborative opportunities including grant applications. This group meets monthly (8x per year). Since April 2008, we have also organized four annual two-day Visiting Professorships for didactic/research sessions in the Division of General Internal Medicine and Grand Rounds in the Department of Oncology (including a joint Departments of Medicine and Oncology Grand Rounds in April 2010)

- 01/2008 – ongoing Institutional Principal Investigator at Johns Hopkins, TBCRC
- 02/2009 – ongoing TBCRC Grant Principal Investigator and Member of the Executive & Steering Committee
Site Principal Investigator at Johns Hopkins (since 2008)
The TBCRC is a clinical research consortium that involves all Breast Cancer SPOREs (including Johns Hopkins) and a few other prominent academic breast cancer research programs in the US as a collaborative group of patient advocates, clinical trialists, physician-scientists, and basic scientists dedicated to innovative, high impact, biologically-driven translational and clinical research. Since 2006, I have been responsible for the establishment of the administrative and coordinating center infrastructure of the Consortium at Johns Hopkins. In 2008, I became institutional PI and am the Consortium principal investigator for our main supporting grants from the Avon Foundation, Breast Cancer Research Foundation, and Susan G. Komen for the Cure. As a member of the scientific and administrative leadership of the Consortium, I share responsibility for strategic decisions regarding its overall funding and for the development and implementation of its academic and research mission.

EDUCATIONAL ACTIVITIES

Educational Publications

Peer-reviewed publications (e.g. consensus statements, expert opinions)

1. Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, **Wolff A**; on behalf of National Comprehensive Cancer Network. NCCN Practice Guidelines for Breast Cancer. *Oncology (Williston Park)*. 2000;14:33-49. (PMID 11195418)
2. **Wolff AC**, Davidson NE. Primary systemic therapy in operable breast cancer. *J Clin Oncol*. 2000;18:1558-69. (PMID 10735905)
3. Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, **Wolff AC** on behalf of the National Comprehensive Cancer Network. Breast Cancer. *J Natl Compr Canc Netw*. 2005;3:238-89. (PMID 16002000)
4. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, **Wolff AC** on behalf of the National Comprehensive Cancer Network. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. *J Natl Compr Canc Netw*. 2006; 4 Suppl 1:S1-26. (PMID 16507275)
5. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, **Wolff AC**, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force. *J Natl Compr Canc Netw*. 2006;4 Suppl 3:S1-22; quiz S23-4. (PMID 16813731)
6. Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, **Wolff AC**. Invasive Breast Cancer. *J Natl Compr Canc Netw*. 2007;5:246-312. (PMID 17439758)
7. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, **Wolff AC**. on behalf of the NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2009;7:122-92. (PMID 19200416)
8. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Inglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, **Wolff AC**. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. *J Natl Compr Canc Netw*. 2009;7(Suppl 6):S1-21. (PMID 19755043)
9. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer LA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, **Wolff AC**. Breast cancer: noninvasive and special situations. *J Natl Compr Canc Netw*. 2010;8:1182-1207. (PMID 20971842)
10. Hammond MEH, Hayes DF, **Wolff AC**, Mangu PB, Temin S. Current Clinical Issues - Guideline Summaries. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for

Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *JOP*. 2010;6:195-197 (PMID 21037871)

11. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, **Wolff AC**, Zellars R. Invasive Breast Cancer. *J Natl Compr Canc Netw*. 2011; 9:136-222. (PMID 21310842)

Invited review articles

1. **Wolff AC**. Systemic therapy. *Curr Opin Oncol*. 1999; 11:468-74. (PMID 10550010)
2. **Wolff AC**, Abeloff MD. Adjuvant systemic management of early stage carcinoma of the breast. *Surg Oncol*. 1999 Aug;8(2):93-101. (PMID 10732961)
3. **Wolff AC**. Systemic Therapy. *Curr Opin Oncol*. 2000; 12:532-40. (PMID 11085452)
4. **Wolff AC**, Davidson NE. New data on adjuvant therapy for breast cancer. *Curr Oncol Rep*. 1999;1:31-7 (PMID 11122795)
5. **Wolff AC**. New strategies for managing metastatic breast cancer. *Oncology* 2000;14: 629-41
6. **Wolff AC**, Davidson NE. Early Operable Breast Cancer. *Curr Treat Options Oncol*. 2000;1:210-20 (PMID 12057163)
7. **Wolff AC**. Systemic Therapy. *Curr Opin Oncol*. 2001;13:436-49. Erratum in: *Curr Opin Oncol* 2002;14:257. (PMID 11673683)
8. **Wolff AC**, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. *The Oncologist*. 2002;7(3):239-45. (PMID 12065797)
9. Sparano JA, Brown DL, **Wolff AC**. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. *Drug Saf*. 2002;25:301-11 (PMID 12020170)
10. **Wolff AC**. Systemic Therapy. *Curr Opin Oncol*. 2002 Nov;14(6):600-8 (PMID 12409649)
11. **Wolff AC**. Liposomal anthracyclines and new treatment approaches for breast cancer. *Oncologist*. 2003;8 Suppl 2:25-30. (PMID 13679593)
12. Zellars R, **Wolff AC**. Local failure and prognostic factors in ductal carcinoma in situ: concentration on recent publications. *Curr Opin Obstet Gynecol*. 2003;15:9-12 (PMID 12544496)
13. **Wolff AC**. Liposomal anthracyclines and new treatment approaches for breast cancer. *Oncologist*. 2003;8(Suppl 2): 25-30
14. Carraway H, **Wolff AC**. Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer. *Cancer Treat Rev*. 2004;30:303-7. (PMID 15059653)
15. **Wolff AC**. Current status of taxanes as adjuvant therapy for early-stage breast cancer. *Int J Fertil Womens Med*. 2005;50:227-9. (PMID 16468473)
16. **Wolff AC**, Davidson NE. Twenty Years of Systemic Therapy in Breast Cancer. *Oncology*. 2006;20,33-40
17. Cianfrocca M, **Wolff AC**. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer. *Oncology (Williston Park)*. 2007;21:63-9. (PMID 17313157)
18. Tan SH, **Wolff AC**. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. *Clin Breast Cancer*. 2007 Feb;7(6):455-64. (PMID 17386122)
19. Briest S, **Wolff AC**. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. *Expert Rev Anticancer Ther*. 2007;7:1243-53. (PMID 17892424)
20. **Wolff AC**. Triple-Negative Invasive Breast Cancer: Adjuvant Treatment Choices After Lumpectomy. *Medscape CME* 2007 (cme.medscape.com/viewarticle/564815)
21. Briest S, **Wolff AC**. What's New in HER2-Targeted Therapy for Breast Cancer? *Medscape CME* 2008 (cme.medscape.com/viewarticle/569533)
22. Tan SH, **Wolff AC**. The role of ovarian ablation in the adjuvant therapy of breast cancer. *Curr Oncol Rep*. 2008;10:27-37. (PMID 18366958)
23. Bao T, **Wolff AC**. First-line Treatment of Triple-Negative and Basal-Like Breast Cancers. *Medscape CME* 2008 (cme.medscape.com/viewarticle/579062)
24. Bao T, **Wolff AC**. Continuing Trastuzumab After Primary Therapy for Locally Advanced Breast Cancer. *Medscape CME* 2008 (cme.medscape.com/viewarticle/583991)
25. Bao T, **Wolff AC**. The Role of Preoperative Systemic Therapy in Breast Cancer. *Medscape CME* 2008 (cme.medscape.com/viewarticle/585420)
26. Higgins MJ, **Wolff AC**. Therapeutic options in the management of metastatic breast cancer. *Oncology (Williston Park)*. 2008;22:614-23 (PMID 18561551)
27. Higgins MJ, **Wolff AC**. New Concepts and Therapeutic Approaches for Early-Stage Breast Cancer. *Medscape CME* 2008 (cme.medscape.com/viewarticle/581968)
28. Bao T, **Wolff AC**. Trastuzumab Dose and Schedule in the Metastatic Setting. *Medscape CME* 2009 (cme.medscape.com/viewarticle/587191)
29. Higgins MJ, **Wolff AC**. Adjuvant Trastuzumab When HER2 Test Results Are Equivocal. *Medscape CME* 2009 (cme.medscape.com/viewarticle/714381)

30. Connolly RM, **Wolff AC**. Pregnancy and fertility with breast cancer: what are the options? *Oncology* (Williston Park). 2009;23:478-81. (PMID 19544687)
31. Connolly RM, **Wolff AC**. Becoming Pregnant after a Diagnosis of Breast Cancer. *Medscape CME* 2009 (cme.medscape.com/viewarticle/707303)
32. Connolly RM, **Wolff AC**. Treating Breast Cancer During Pregnancy. *Medscape CME* 2009 (cme.medscape.com/viewarticle/704511)
33. Connolly RM, **Wolff AC**. Adjuvant Endocrine Therapy: Are Treatment-Related Symptoms "Good News?" *Medscape CME* 2010 (<http://cme.medscape.com/viewarticle/730865>)
34. Connolly RM, **Wolff AC**. International disparity in breast cancer outcomes: the time to close the gap is now. *Oncology* (Williston Park). 2010; 24:1236-7. (PMID 21192566)
35. **Wolff AC**. Active Cancer Treatment during Pregnancy—Two perspectives on timing and drug choice. *ASCO Connection* 2011. <http://connection.asco.org/ASCOConnectionMagazine/tabid/73/aff/19/aft/510/afv/topic/Default.aspx#510>

Editorials

1. Sparano JA, **Wolff AC**, Brown D. Troponins for predicting cardiotoxicity from cancer therapy. *Lancet*. 2000;356:1947-8. (PMID 11130520)
2. **Wolff AC**, Abeloff MD. Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so. *J Natl Cancer Inst*. 2002;94:1041-3. (PMID 12122089)
3. **Wolff AC**, Desch CE. Clinical Practice Guidelines in Oncology: Translating Evidence into Practice (and Back). *JOP*. 2005;1:160-161 (PMID 20871699)
4. **Wolff AC**, Davidson NE. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. *J Clin Oncol*. 2006;24:4949-51. (PMID 17075110)
5. Higgins MJ, **Wolff AC**. The androgen receptor in breast cancer: learning from the past. *Breast Cancer Res Treat*. 2010 Mar 31. [Epub ahead of print] (PMID 20354779)
6. **Wolff AC**, Dowsett M. The estrogen receptor: the never ending story. *J Clin Oncol* 2011 (*in press*)

Letters, correspondence

1. **Wolff AC**, Hammond MEH, Schwartz JN, Hayes DF. Reply to A. Raji and to K. Vang Nielsen et al *J Clin Oncol* 2007; 25:4021-3 (<http://jco.ascopubs.org/content/25/25/4021.full?sid=5e576a35-eb38-40ee-86d2-213f284af819>)
2. Hammond EH, **Wolff AC**, Hayes DF, Schwartz JN. Reply to G. Sauter et al. *J Clin Oncol*. 2009;27:e153-4; author reply e155-7 (PMID 19738107)
3. Hammond MEH, Hayes DF, **Wolff AC**. Breast Cancer Tests. Letter to the Editor, *New York Times*, April 29, 2010 (www.nytimes.com/2010/04/29/opinion/lweb29cancer.html?scp=3&sq=wolff&st=cse) in response to A1 page article "Cancer Fight: Unclear Tests for New Drug" (<http://www.nytimes.com/2010/04/20/health/research/20cancer.html?scp=1&sq=cancer%20fight:%20unclear%20tests%20for%20new%20drug&st=cse>) published April 19, 2010).

Book Chapters, Monographs

1. **Wolff AC**, Davidson NE. Use of SERMs for the adjuvant therapy of early-stage breast cancer. *Ann N Y Acad Sci*. 2001;949:80-8. (PMID 11795384)
2. **Wolff AC**, Paik S, Press MF. HER2 as a predictive marker: Why bother testing? *J Clin Oncol*. 2008 (ASCO Annual Meeting Educational Book)
3. **Wolff AC**, Wood WC. Local and Regional Recurrence of Breast Carcinoma. In *Prognosis and Outcome Expectancy of Surgical Diseases* (McKellar DP, Reiling RB, eds) Quality Medical Publishing, St. Louis, 1997
4. **Wolff AC**, Lange JR, Davidson, NE Occult Primary Cancer with Axillary Nodal Metastases. In *Advanced Therapy of Breast Disease* (Singletary SE, Robb G, eds), BC Decker Publishers, Inc, St. Louis. 2000:191-5.
5. **Wolff AC**, Stearns V, Davidson NE. Adjuvant Systemic Therapy of Breast Cancer. In *The Breast*, 3rd edition (Bland, Copeland, eds.), Elsevier Science, 2004
6. Abeloff MD, **Wolff AC**, Weber B, McCormick B, Wood WC. Cancer of the Breast. In *Clinical Oncology*, 3rd edition (Abeloff, Armitage, Niederhuber, Kastan, and McKenna, eds), Churchill Livingstone, 2004
7. Abeloff MD, **Wolff AC**, Zaks T, Weber B, Sacchini, V, McCormick B. Cancer of the Breast. In *Abeloff's Clinical Oncology*, 4th edition (Abeloff, Armitage, Niederhuber, Kastan, McKenna, eds), Elsevier, 2008
8. Tan SH, **Wolff AC**. Treatment of Metastatic Breast Cancer: Chemotherapy. In *Diseases of the Breast*, 4th edition (Harris, Lippman, Morrow, Osborne, eds), Lippincott Williams & Wilkins, 2009

Other media (films, videos, CD-ROMs, slide sets, etc)

1. **Wolff AC**: Breast Cancer. <http://pier.acponline.org/physicians/diseases/d192/d192.html>. *In*: PIER [online database]. Philadelphia, American College of Physicians-American Society of Internal Medicine, 2002.
2. **Wolff AC**. Current Issues in Metastatic Breast Cancer: An Expert Interview. *Medscape CME* 2005 (cme.medscape.com/viewarticle/519889)
3. Winer EP, **Wolff AC**, Newman LA, Buchholz, T, Finestone S. ASCO 2007: Multidisciplinary Breast Cancer Management. *Medscape* 2007: Multidisciplinary Breast Cancer Management (cme.medscape.com/viewarticle/558918)

4. **Wolff AC**, Ligibel, JA, Schott A. When Breast Cancer Treatment Ends: Helping Survivors Stay Healthy. Medscape CME 2008 (cme.medscape.com/viewarticle/585020)
5. Winer EP, Buchholz TA, Finestone SA, Newman LA, **Wolff AC**. Breast Cancer in Older Women (slides with Transcript). Medscape CME 2008 (cme.medscape.com/viewarticle/577229)
6. Jacobson JO, **Wolff AC**. Evidence-Based Medicine: Do Clinical Practice Guidelines Contribute to Better Patient Care? -- An Expert Interview. Medscape CME 2009 (cme.medscape.com/viewarticle/589088)
7. Perou CM, **Wolff AC**. Developing Tools to Identify and Personalize Treatment of Breast Cancer: An Expert Interview. Medscape CME 2010 (cme.medscape.com/viewarticle/714996)
8. **Wolff AC**. Specialist Answers Questions About Breast Cancer (translated, Veja Magazine 2010, a top circulation Brazilian weekly news magazine) (veja.abril.com.br/noticia/saude/cancer-de-mama-especialista-responde-as-duvidas-dos-leitores and veja.abril.com.br/noticia/saude/pergunta-aos-especialistas)
9. **Wolff AC**, Bantug E, Shockney L, and Peairs, K. Survivorship Videos, Breast Cancer Video Gallery, Johns Hopkins Breast Cancer Program, a project funded by Susan G. Komen for the Cure Maryland (http://www.hopkinsmedicine.org/avon_foundation_breast_center/patient_information/videos/index.html#survivorship).
10. **Wolff AC**. Interview by Mônica Manir, editor for Caderno Alias (“Week in Review”) at the time of the death of Vice-President José Alencar (translated, O Estado de São Paulo, the largest Brazilian newspaper, April 3 2011) (<http://www.estadao.com.br/noticias/suplementos,a-mais-dura-campanha,700817,0.htm>)
11. Bantug ET, **Wolff AC**. Johns Hopkins Breast Cancer Survivorship Website. Dr. Wolff has secured external funding and provided scientific/editorial oversight to Elissa Bantug, BS, MHS (Survivorship Coordinator) for the creation of this website, videos, blogs, a provider intranet, and related materials (http://www.hopkinsmedicine.org/avon_foundation_breast_center/treatments_services/survivor_care/index.html) (<http://cancer-matters.blogs.hopkinsmedicine.org/author/ebantug1/>)

Teaching

Classroom instruction

1995 – 1998	2 nd year Medical Students Clinical Methods Course, Emory University
1998 – 1999	2 nd year Medical Student Pathophysiology Course, JHUSOM
1998 – ongoing	Lecturer, Annual Fellowship Orientation Program, Dept of Oncology, JHUSOM

Clinical instruction

1998 – ongoing	Inpatient Consult and Solid Tumor Services, 4-6 weeks/year, Johns Hopkins
1998 – ongoing	Faculty Outpatient Continuity Clinic (various residents and fellows throughout the year, 2 days/week, East Baltimore and Green Spring Station clinics, Johns Hopkins)
2004 – ongoing	Monthly Fellow Outpatient New Patient Breast Cancer Clinic (1 st year fellows, supervisory role every 2 nd or 3 rd month)

Workshop/Seminars

11/04	Panelist, Workshop on Translational Research in Cancer, Tumor Response (Cancer Imaging Program, NCI, Bethesda, MD)
3/07	Speaker and Member of Organizing Committee. State of the Science Conference on Preoperative Therapy in Invasive Breast Cancer (Cancer Therapy and Evaluation Program, Division of Cancer Diagnosis and Treatment, NCI, Bethesda, MD).
10/07	Speaker, NCI/FDA/Industry Workshop on Development of Markers for Clinical Decision-Making (Bethesda, MD)
5/11	Invited Speaker, Concordance/discordance issues from HER2 testing: Clinical experience. Breast Cancer Steering Committee, Clinical Trials Planning Meeting, Next Generation Phase III Studies for HER2-Positive Breast Cancer, NCI/CTEP, Rockville, MD (upcoming)

Mentoring Advisees

2000 -2001	Smitha Krishnamurthi, MD, post-doctoral fellow, currently Assistant Professor of Medicine, Case Western Reserve University. Served as mentor for a specific clinical research project “A pharmacokinetic (PK) and pharmacodynamic study of doxorubicin and docetaxel combinations plus marimastat (AT/M) in metastatic breast cancer”, presented at the ASCO 2001 meeting.
2002 – 2003	Wells Messersmith, MD, post-doctoral fellow, currently Associate Professor of Medical Oncology and Director of Gastrointestinal Medical Oncology, University of Colorado. Served as mentor for clinical research project “Phase I study of continuous weekly dosing of dimethyl benzoylphenylurea (BPU) in patients with solid tumors” (ASCO 2003 Travel Award and SKCCC Fellows Research Day 2003 Best Clinical Research Project)

- 2008 – ongoing Ana Maria Gonzalez-Angulo, MD, Associate Professor of Oncology, MDACC, Houston. Currently serve in her Mentoring Committee for a 2009 Komen for the Cure Catalyst Award on Disparities project “Chemotherapy Resistance in Hispanic and African American Patients”
- 2008 – ongoing Ron Bose, MD, PhD, Assistant Professor of Medicine, Washington University School of Medicine, St. Louis. Currently serve in his Mentoring Committee for a 2009 awarded Komen for the Cure Catalyst Award on project “Proteomic Identification and Reversal of Mechanisms of Herceptin Resistance in Her2/neu Positive Breast Cancer”
- 2009 – 2010 Michaela Higgins, MB.BCh, post-doctoral fellow, currently Attending Physician, Massachusetts General Hospital. Served as a co-mentor for a specific clinical research project on detecting PK3CA mutations in patients with metastatic breast cancer. ASCO 2011 Annual Meeting Poster Discussion Session.
- 2009 – ongoing Aditya Bardia, MD, MPH, post-doctoral fellow. Serve as a mentor for a specific clinical research project “Circulating Tumor Cells (CTCs) and CA27.29 as Predictors of Outcome in Metastatic Breast Cancer (MBC) Patients in the Prospective TBCRC 005 Biomarker Study.” ASCO 2010 Annual Meeting Clinical Science Symposium oral presentation, Travel Award, and Merit Award.
- 2010 – ongoing Rosin M. Connolly, MB.BCh, post-doctoral fellow. Serve as mentor for a specific clinical research project “Docetaxel Pharmacokinetics is Not Altered by CYP3A4 Inhibition with Imatinib: A Pharmacokinetic/Pharmacodynamic (PK/PD) Study in Metastatic Breast Cancer” (published 2011), and various review articles and invited commentaries.

Thesis committee

- 2/09 Jakir Hossain, served as member of his Graduate Board Oral exam, JHU Biomedical Engineering

Educational Program Building/Leadership

- 1999 – 2006 Co-Director, Johns Hopkins Medical Oncology Fellowship Program
In this role, I co-directed with Dr. Ross Donehower the overall day-to-day activities of the fellowship program, its recruitment process, and its long-term planning. I also led the internal effort to bring our Fellowship Program in compliance with newly established ACGME rules in the mid-2000s and prepare it for a successful site visit. I stepped down from this role in 2006 in view of my other research-related responsibilities, but have remained an ad-hoc member of the Fellowship Selection Committee.

CLINICAL ACTIVITIES

Certification

Medical, other state/government licensure

- 1988 ECFMG Certificate (permanent certification #413-744-4)
1989 FLEX Examination
1990 State of Maryland (License to Practice Medicine #D39774)
1995 State of Georgia (License to Practice Medicine #039982 inactive)

Board Certification

- 1991 ABIM Internal Medicine (Recertified in 2000, valid until 2011)
1995 ABIM Medical Oncology (Recertified in 2000, valid until 2014)

Clinical (Service) Responsibilities

- 1995 – 1998 Emory University Hospital, oncology consults and inpatient unit
The Emory Clinic, outpatient oncology practice
Atlanta VAMC, medicine inpatient service and consults, outpatient oncology practice
- 1998 – present Johns Hopkins Hospital and Cancer Center, attending inpatient solid tumor and consult services (4-6 weeks per year), attending outpatient clinic (2 full days each week, Green Spring Station and East Baltimore), fellow new patient monthly breast clinic (half day every 2nd or 3rd month)

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

System Innovation and Quality Improvement Publications:

1. **(Ref 48)** Kantsiper M, McDonald EL, Geller G, Shockney L, Snyder C, **Wolff AC**. Transitioning to Breast Cancer Survivorship: Perspectives of Patients, Cancer Specialists, and Primary Care Providers. *J Gen Intern Med.* 2009;24(Supp 2):S459 (PMID 19838851)

System Innovation and Quality Improvement efforts within JHM:

2007– ongoing Johns Hopkins Breast Cancer Survivorship Program, leader (1.2 months funded effort). I lead a multidisciplinary and cross-school institutional program and secured external funding in order to educate cancer specialists and primary care providers at Hopkins and elsewhere, pilot improved practices in breast cancer survivorship, and establish web-based AV and social media materials to educate patients and providers alike.

System Innovation and Quality Improvement efforts outside of JHM:

- 2002 – 2008 ASCO Health Services Committee, member 2002-2005, panel leadership 2006-2008, committee chair 2006-2007 (unfunded effort), Alexandria, VA. This ASCO panel creates and oversees all ASCO clinical practice guideline documents. I also led the establishment of the Toolbox concept for guideline implementation, dissemination, and evaluation (currently the GUIDE subcommittee).
- 2005 – ongoing ASCO/College of American Pathologists Panel on HER2 Testing, co-chair (unfunded effort), Alexandria, VA. I proposed and co-established the international multidisciplinary guideline panel, first authored guideline document, guided dissemination process, and co-leads update panel.
- 2007 – 2011 ASCO Quality Advisory Group and Quality Care Committee, member 2007-2011 (unfunded effort), Alexandria, VA. Oversees all internal and external ASCO quality of care activities.
- 2008 – ongoing ASCO/College of American Pathologists Panel on Immunohistochemistry Testing for ER/PgR in Breast Cancer, co-chair (unfunded effort), Alexandria, VA. I proposed and co-established the international multidisciplinary guideline panel, senior authored guideline document, guided dissemination process, and co-lead update panel.
- 2009 – ongoing Komen/ASCO Foundation Breast Cancer Registry Pilot Program Steering Group, member (unfunded effort), Alexandria, VA. The committee oversees a pilot project to establish a web-based survivorship registry in early stage breast cancer being piloted in oncology practices around the country.

Production of guidelines and/or protocols

- 2000 – annual (Educ Refs 1, 3-9, 11) NCCN Breast Cancer Guideline Panel; member, Philadelphia, PA, annual guideline update
- 2004 (Ref 14) ASCO technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer; panel member, Alexandria, VA, guideline recently updated
- 2005 (Ref 17) ASCO Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer; panel member, Alexandria, VA, guideline undergoing update
- 2006 (Ref 21) ASCO Update of Recommendations for the Use of White Blood Cell Growth Factors; panel member, Alexandria, VA, guideline active
- 2006 (Ref 23) ASCO Update of the Breast Cancer Follow-up and Management Guideline in the Adjuvant Setting; panel member, Alexandria, VA, guideline active.
- 2007 (Refs 25, 26, 64) ASCO/CAP HER2 Testing Guideline Panel; co-chair, Alexandria, VA, guideline being updated.
- 2008 (Refs 55, 56, 58, 64; Educ Ref 10) ASCO/CAP Hormone Receptor Testing Guideline Panel; co-chair, Alexandria, VA, guideline active

System Innovation and Quality Improvement Program Building/Leadership:

None

System Innovation and Quality Improvement Extramural Funding:

(Also listed in Current Grant section)

4/1/08 – 3/31/12 A Survivorship Program for Breast Cancer: A Transition for Patients and Providers
90033368
Susan G. Komen for the Cure Maryland
\$187,000
Principal Investigator, 1.2 calendar months; Note: The major goal of this project is to establish breast cancer follow-up care strategies for survivors and their health care providers and a comprehensive clinical and educational services model adaptable for use elsewhere.

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

Emory University School of Medicine and Atlanta VAMC

1995 – 1998 Member, Task Force on Genetic Risk Assessment in Oncology (Chair, Education Subcommittee)
1995 – 1998 Member, Clinical Research Review Committee – Winship Cancer Center
1995 – 1998 Member, Cancer Committee – Emory University Hospital and Atlanta VAMC
1995 – 1998 Member, Pain Committee – Atlanta VAMC
1995 – 1998 Acting Leader, Breast Cancer Working Group – Winship Cancer Center
1995 – 1998 Institutional Co-PI ECOG Grant & Senior Investigator at Atlanta VAMC
1997 – 1998 Chief, Hematology & Oncology Section – Atlanta VAMC

Johns Hopkins University School of Medicine

1998 – 2000 Medical Oncology Representative, Breast Center Steering Committee
1999 – 2000 Member, Women At-Risk Program Planning Committee
1999 – present Member, Medical Oncology Fellowship Program Selection Committee (ad-hoc since 2006)
1999 – 2006 Co-Director, Medical Oncology Fellowship Program
2001 – 2008 Member, Cancer Center Educational Committee
2008 – present Member, JHUSOM CME Advisory Board
2008 – 2009 Chair, Search Committee for a new Breast Cancer Clinical Faculty
I led a successful national search that ultimately led to the recruitment of Robert Miller, MD as a fulltime clinician in the Breast Cancer Program at Green Spring Station. Dr. Miller ran a successful clinical practice in Sacramento, CA and in 2010 completed a 3-year term in ASCO's Board of Directors.
2010 – 2012 Member, Cancer Center Awards Committee
2010 Co-Chair, Cancer Center Scientific Research Review Committee (CRC)
2011 Chair, Cancer Center Scientific Research Review Committee (CRC)

Editorial Activities

Editorial Board appointments

2005 – present *ASCO Connection* (www.ascoconnection.org, previously ASCO News and Forum)
2008 – present *Journal of Clinical Oncology* (jco.ascopubs.org)
2009 – present *Breast Cancer Research* (breast-cancer-research.com)

Journal Reviewer

2000 - present *Agency for Healthcare Research and Quality (AHRQ)*
Breast Cancer Research and Treatment
Canadian Medical Journal Association
Cancer (American Cancer Society)
Cancer Research
Clinical Cancer Research
Clinical Evidence (BMJ) – ACP/ASIM
Clinical Pharmacokinetics
Journal of American Medical Association (JAMA)
Journal of Clinical Oncology
Journal of the National Cancer Institute
New England Journal of Medicine
Oncology
The Oncologist

Advisory Committees, Review Groups/Study Sections

- 2000 – present Member, Breast Cancer Guidelines Panel, National Comprehensive Cancer Network
- 2001 – present Ad-hoc grant peer-reviewer, Cancer Research UK Clinical Trials Committee
- 2001 – present Ad-hoc grant peer-reviewer, Eastern Cooperative Oncology Group
- 2002 – 2008 Member, Grant Review Panel, Susan G. Komen for the Cure Maryland
- 2006 Peer-Reviewer, NIH Subcommittee H (Cooperative Groups)
- 2007 – 2008 Consultant to Johns Hopkins Evidence Practice Center (PI, Eric Bass), Task Order “Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes”
- 2007 Member of Expert Panel to Blue Cross Blue Shield Technology Evaluation Center, Task Order “HER2 Testing to Manage Patients with Breast or Other Solid Tumors”
- 2007 – 2010 Member, Steering Committee, Medscape Breast Cancer Curriculum funded by Susan G. Komen for the Cure (<http://cme.medscape.com/curriculum/breastcancer>)
- 2008 – 2011 Board Member, American College of Surgeons’ National Accreditation Program for Breast Centers (ASCO representative)
- 2008 Grant Review Panel (Promise Grant and Biomarker-based Diagnosis & Prognosis Panel (BDP-2), Susan G. Komen for the Cure)
- 2008 Member, National Quality Forum Clinician Level Cancer Steering Committee
- 2009 – present Member, External Advisory Board, North Central Cancer Treatment Group
- 2010 – present Member, External Advisory Board, Breast Cancer SPORE, UAB at Birmingham
- 2009 Speaker, Institute of Medicine’s Committee on Comparative Effectiveness Research
- 2010 Peer-Reviewer, NIH Subcommittee H (Cooperative Groups)
- 2010 – 2012 Scholar, Susan G. Komen for the Cure Scientific Advisory Council

Professional Societies

- 1991 – present American College of Physicians
- 1991 – 2004 Member, American College of Physicians
- 2004 – present Fellow, American College of Physicians
- 1993 – present American Association for Cancer Research
- 1993 – 1995 Associate Member, American Association for Cancer Research
- 1995 – present Member, American Association for Cancer Research
- 1995 – present Eastern Cooperative Oncology Group
- 1995 – present Member, Eastern Cooperative Oncology Group
- 1999 – present Member, Breast Committee, Eastern Cooperative Oncology Group
- 2010 – present Co-chair, Developmental Therapeutics Working Group, Breast Committee, Eastern Cooperative Oncology Group
- 1995 – present American Society of Clinical Oncology
- 1995 – present Active Member, American Society of Clinical Oncology
- 2002 – 2008 Member, Health Services Committee, American Society of Clinical Oncology
- 2002 – present Member, Colony Stimulating Factors Update Panel
- 2002 – present Member, Lymphatic Mapping Technology Assessment Panel
- 2003 – 2004 Member, Scientific Annual Meeting Program Committee
- 2004 – 2005 Chair, Guideline Dissemination and Implementation Panel
- 2004 – 2008 Member, Aromatase Inhibitors Guideline Panel
- 2004 – 2008 Member, Adjuvant Endocrine Therapy Guideline Panel
- 2004 – 2005 Member, Oncology Workforce Study Group
- 2005 – present Member, Breast Cancer Surveillance Guideline Panel
- 2005 – 2008 Member, Quality Advisory Group
- 2006 – 2008 Member, Executive Leadership, Health Services Committee
- 2006 – present Co-Chair, ASCO/College of American Pathologists (CAP) HER2 Testing Tech Assessment Panel
- 2007 – 2008 Chair, Health Services Committee
- 2008 – present Co-Chair, ASCO/CAP ER/PgR Testing Guideline Panel
- 2008 – 2010 Member, Education Annual Meeting Program Committee
- 2009 – 2010 Leader, Breast Cancer Track, ASCO 2010 Program Committee
- 2008 – 2011 Member, Quality of Care Committee
- 2009 – present Member, Komen/ASCO Foundation Breast Cancer Registry Pilot Program Steering Group
- 2002 – present European Society of Medical Oncology
- 2002 – present Member, European Society of Medical Oncology

Conference Organizer, Session Chair

- 2003 ASCO Annual Meeting – Member, Scientific Program Committee
Session Chair & Oral Discussant, Advanced Breast Cancer Poster Discussion
- 2004 ASCO Annual Meeting – Member, Scientific Program Committee
Oral Discussant, Early Stage Breast Cancer Oral Session
- 2006 ASCO Annual Meeting – Education Session Chair, Adjuvant Endocrine Therapy in Breast Cancer
- 2007 NCI of the Science Symposium on Preoperative Chemotherapy in Breast Cancer
– Member of Organizing Committee and Writing Committee, and Speaker
- 2007 ASCO Annual Meeting – Scientific Session Co-Chair, Metastatic Breast Cancer
- 2009 1st Global Breast Cancer Conference, Seoul, Korea – Member, International Steering Committee
- 2008 ASCO Annual Meeting – Education Session Chair, HER2 Testing in Breast Cancer: Why Bother?
- 2010 ASCO Annual Meeting – Leader, Breast Cancer Education Track
Co-Chair, Clinical Science Symposium, Preoperative Therapy
- 2010 San Antonio Breast Cancer Symposium – Reviewer, Scientific Program Committee
- 2011 2nd Global Breast Cancer Conference, Seoul, Korea – Member, International Steering Committee

RECOGNITION

Awards, Honors

- 1993 – 1994 Sandoz Fellow in Medicine
- 1997 Invited Trainee, ASCO Task Force on Cancer Genetics Education
- 1997 Invited Trainee, ASCO/AACR Methods in Clinical Cancer Research
- 2001 – 2003 Invited Trainee, Innovators in Breast Cancer Junior Faculty Workshop (Chair, Gabriel Hortobagyi)
- 2004 Invited Trainee, ASCO/AACR/NCI/FDA Accelerating Anticancer Agent Development and Validation Training Workshop
- 2004 Fellow, American College of Physicians
- 2007 Cameo Award, Maryland Affiliate of Susan G. Komen for the Cure
- 2008 Invited Participant, Leadership Development Program, JHU School of Medicine
- 2009 NCI Cancer Clinical Investigator Team Leadership Award
- 2010 ASCO Statesman Award

Invited Talks, Panels:

- 10/96 Speaker, Breast Health Forum, Breast Cancer Awareness Month Celebrations, Emory University, Atlanta, GA
- 6/97 Speaker, Medicine & Primary Care Grand Rounds, The Medical Center, Columbus GA
- 6/97 Speaker, Breast Cancer Panel & Celebration of Living, Emory University, Atlanta, GA
- 2/98 Speaker, Ob/Gyn Grand Rounds, The Medical Center, Columbus, GA
- 6/98 Speaker, Emory University, Recent Advances in the Treatment of Solid Tumors and Hematologic Malignancies, Atlanta, GA
- 6/98 Speaker, Emory University, Breast Cancer Panel & Celebration of Living, Atlanta, GA
- 10/98 Speaker, Cancer Genetics in the 1990's, Oncology Nursing Update Symposium, Atlanta, GA
- 10/98 Speaker, Charting a Course for Control & Prevention in Maryland, Maryland State Council on Cancer Control, Baltimore, MD
- 10/98 Speaker, Reach to Recovery Program, Mid-Atlantic Division, American Cancer Society, Baltimore, MD
- 3/99 Speaker, Breast Cancer Update, 2nd Annual John R. Marsh Oncology Program, Robinwood Medical Center, Hagerstown, MD
- 3/99 Speaker, Hormonal Therapy in Early Stage Disease, The Johns Hopkins Oncology Center's 25th Annual Symposium on Diagnosis and Treatment of Neoplastic Disorders, Baltimore, MD
- 3/99 Speaker, Topics in Breast Cancer and Internal Medicine, Medical Grand Rounds, Mercy Hospital, Baltimore, MD
- 4/99 Speaker, Hormone Replacement Therapy and Breast Cancer Risk, American Cancer Society/Komen Foundation Symposium on Breast Cancer, Baltimore, MD
- 5/99 Speaker, Update on the Treatment of Advanced Breast Cancer, Baltimore, MD
- 7/99 Speaker, The Role of Tamoxifen in the Breast Cancer Prevention, Hagerstown, MD
- 8/99 Speaker, Herceptin® and Liposomal Anthracyclines in Metastatic Breast Cancer, Genentech Investigators Meeting, San Francisco, CA
- 8/99 Speaker, Tamoxifen: Role in Prevention of Breast Cancer, Peninsula Regional Medical Center, Salisbury, MD
- 10/99 Oral Discussant, Neoadjuvant Chemotherapy in Breast Cancer Scientific Session
Speaker, Modern Strategies for the Treatment of Breast Cancer; The Role of Taxanes in Breast Cancer,

- 8/99 11th Brazilian Congress of Clinical Oncology, Florianopolis, Brazil
Speaker, Making a Multi-disciplinary Breast Center Work, Seeking Excellence in Breast Cancer Care Conference, Baltimore, MD
- 10/99 Speaker, Novel Therapies for Breast Cancer, Seeking Excellence in Breast Cancer Care Conference, Baltimore, MD
- 10/98 – 1/00 Speaker, The Role of Taxanes and Anthracyclines in Advanced Breast Cancer, Atlanta, GA; Orlando, FL; Dana Point, CA; Jacksonville, FL; Scottsdale, AZ; Palm Beach, FL
- 11/99 Speaker, Risk Reduction Strategies in Early Stage Breast Cancer, Annual Meeting of the Maryland Cancer Chapter - American College of Surgeons, Baltimore, MD
- 1/00 Speaker, The Role of Tamoxifen in the Breast Cancer Treatment and Prevention, Fallston, MD
- 2/00 Speaker, Update on Taxanes, Baltimore, MD
- 2/00 Speaker, Breast Cancer Update, Baltimore, MD
- 3/00 Speaker, Anti-Estrogen Drugs in Breast Cancer, Camp Hill, PA
- 3/00 Speaker, Management of HER2 Negative Metastatic Breast Cancer, Orlando, FL
- 9/00 Speaker, The Role of Taxanes in Breast Cancer, Central Pennsylvania Hematology-Medical Oncology Associates, Lemoyne, PA
- 9/00 Speaker, The Role of Taxanes in Metastatic Breast Cancer, Grand Rounds, Sinai Hospital of Baltimore,
- 9/00 Speaker, Topics in Breast Cancer, House Staff Retreat, Good Samaritan Hospital of Baltimore, MD
- 9/00 Speaker, Breast Cancer Update: Topics in Risk Reduction and Treatment, City Hospital, Shepherds Town, WV
- 10/00 Speaker, New Drugs in Breast Cancer, 9th Annual Breast Cancer Conference, Fairfax Hospital, VA
- 2/01 Speaker, The ECOG Experience, Adjuvant Use of Taxanes in Breast Cancer, Zurich, Switzerland
- 8/01 Speaker, Management of Patients with Locally Advanced Breast Cancer, 11th Annual Hematology Oncology Review, Mayo Clinic, Jacksonville, FL
- 8/01 Speaker, Breast Cancer Update, Hematology-Oncology Grand Rounds, Washington Hospital Center, Washington, DC
- 9/01 Speaker, The Treatment of Metastatic Breast Cancer, Meet the Professor Panelist
Plenary Session Speaker, Approaches for the Adjuvant Treatment of Breast Cancer
12th Brazilian Congress of Clinical Oncology, Florianopolis, Brazil
- 10/01 Speaker, Breast Cancer Update, Hematology-Oncology Grand Rounds, Emory University, Atlanta, GA
- 10/01 Speaker, Current Concepts in Breast Cancer Treatment, Internal Medicine Grand Rounds, Crozer-Chester Medical Center, Upland, PA
- 11/01 Speaker, The Treatment of Breast Cancer: Can We Do More With Less? Hematology-Oncology Grand Rounds, University of Maryland, Baltimore, MD
- 11/01 Speaker & Panelist, Hormone Replacement Therapy and Breast Cancer Risk, A Woman's Journey, Johns Hopkins Medicine, Baltimore, MD
- 2/02 Speaker, Breast Cancer for the Internist, House Staff Rounds, Good Samaritan Hospital of Baltimore, Baltimore, MD
- 4/02 Speaker, Implementing Novel Research Findings for Early Detection and Prevention: Are They Ready for Prime-Time? Jane Cremer Foundation, Racine, WI
- 4/02 Speaker, Hype and Hope: Are We Really Moving Forward in the Fight Against Breast Cancer? Jane Cremer Foundation, Racine, WI
- 4/02 Speaker, Emerging Standards in Anthracycline-Regimens in Adjuvant Breast Cancer
Oncology Nursing Society Annual Meeting, Washington, DC
- 5/02 Speaker, Update on Hormonal Therapy for the Treatment of Breast Cancer; 4th Annual Hem/Onc Seminar for Primary Care Physicians, Upper Chesapeake Medical Center, Belair, MD
- 5/02 Speaker, Update on Cancer Screening Guidelines, Promise and Progress, A Special Seminar on Breast Cancer Prevention, Detection, and Early Diagnosis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
- 6/02 Speaker, Clinical Research in Breast Cancer: What are the Big Questions? Cancer Center Research Seminar, Johns Hopkins Medicine, Baltimore, MD
- 6/02 Speaker, Pre-Operative (Primary) Systemic Therapy: Should It Become The New Standard? Cancer Center Research Seminar, Johns Hopkins Medicine, Baltimore, MD
- 6/02 Speaker, Use (and Misuse) of Prognostic and Predictive Factors in Breast Cancer, Breast Cancer Research Program Seminar, Johns Hopkins Medicine, Baltimore, MD

- 10/02 Speaker, Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer, Cancer Center Grand Rounds, Johns Hopkins Medicine, Baltimore, MD
- 6/03 Session Chair and Discussant, ASCO Meeting Poster Discussion Session (Late Breast Cancer) ASCO annual meeting, Chicago, IL
- 6/03 Speaker, Post-ASCO Highlights, Oncology Nursing Society, Maryland Chapter, Baltimore, MD
- 6/03 Speaker, Developing New Treatments in Breast Cancer, Breast Cancer Research Program Seminar, Johns Hopkins Medicine, Baltimore, MD
- 8/03 Speaker, Post-ASCO Highlights, Network for Oncology Communication & Research, Orlando, FL
- 9/03 Speaker, Preoperative Systemic Therapy in Breast Cancer, Anne Arundel Medical Center, Baltimore, MD
- 9/03 Speaker, Adjuvant Endocrine Therapy in Breast Cancer, Holy Cross Hospital Annual Breast Cancer Symposium, Silver Spring, MD
- 10/03 Speaker, Prognostic Factors in Breast Cancer, National Comprehensive Cancer Network Symposium, New York, NY
- 10/03 Speaker, Prognostic Factors in Breast Cancer, National Comprehensive Cancer Network Symposium, Atlanta, GA
- 11/03 Speaker, Advances in Systemic Therapy of Breast Cancer, Medical College of Wisconsin Breast Cancer Symposium, Milwaukee, WI
- 2/04 Visiting Faculty, SERMs and Aromatase Inhibitors in the Adjuvant Setting, University of Oklahoma Cancer Center, Oklahoma City, OK
- 4/04 Speaker, Minimally Involved Axillary Nodes: Pathologic Assessment and Impact on Treatment and Outcomes, Current Concepts in the Multidisciplinary Management of Breast Cancer, Johns Hopkins Medicine, Baltimore, MD
- 6/04 Discussant, ASCO Meeting Breast Cancer Oral Presentation Session, ASCO annual meeting, Chicago, IL
- 6/04 Speaker, Breast Cancer Update, American Council of Life Insurers, Baltimore, MD
- 7/04 Speaker, Breast Cancer Update, Johns Hopkins Internal Medicine Board Review, Baltimore, MD
- 11/04 Panelist, MR Workshop on Translational Research in Cancer - Tumor Response, Cancer Imaging Program, National Cancer Institute, Bethesda, MD
- 3/05 Lecturer, Early Stage Breast Cancer, San Antonio Symposium 2004 Update, Albert Einstein College of Medicine, New York, NY
- 3/05 Speaker, New Approaches to Hormonal Therapy for Breast Cancer in the Adjuvant Setting, National Comprehensive Cancer Network Annual Meeting, Hollywood, FL
- 3/05 Lecturer, Clinical Problems in Breast Cancer, PET/CT and SPECT/CT Imaging of Cancer for Radiologists and Nuclear Physicians, Johns Hopkins Medicine, Baltimore, MD
- 5/05 Speaker, Age as a Prognostic/Predictive Factor, NCCN Breast Adjuvant Task Force, Chicago, IL
- 5/05 Faculty, From Fellow to Faculty: Career Advice for the Clinical Investigator, ASCO annual meeting, Orlando, FL
- 10/05 Speaker, Improving Patient Outcome with Targeted Therapy, 7th Lynn Sage Breast Cancer Symposium, Northwestern University, Chicago, IL
- 10/05 Speaker, Minimally Involved Lymph Nodes: Impact on Outcome and Therapy Decisions, Instituto Nacional do Cancer, Rio de Janeiro, Brazil
- 10/05 Speaker, Terapia Sistêmica: Aspectos Controversos
Cancer de Mama: Quimioterapia Primária
Hormonioterapia Adjuvante
Avancos no Tratamento Adjuvante do Cancer de Mama
XIV Congresso Brasileiro de Oncologia Clínica and XV Congresso Integrado Latino Americano de Cancerologia, Rio de Janeiro, Brazil
- 12/05 Speaker, Risk Assessment and Prognostic Factors, NCCN symposium at San Antonio Breast Cancer Symposium, San Antonio, TX
- 2/06 Speaker, HER2 as a Predictive Marker for non-Trastuzumab Therapy, NCCN HER2 panel meeting, Chicago, IL
- 3/06 Speaker, Predicting the Future: The Role of Predictive Markers in Breast Cancer Care, Cancer Center Grand Rounds, Cleveland Clinic Foundation, Cleveland, OH
- 4/06 Speaker, Breast Cancer Update, National Breast Cancer Coalition Advocacy Training, Washington, DC
- 4/06 Speaker, Predicting the Future: The Use of Predictive Markers in Breast Cancer Therapy, Pathology Grand Rounds, Johns Hopkins University, Baltimore, MD

- 4/06 Speaker, Update on Aromatase Inhibitors & Sentinel Node: Questions and Challenges, Breast Cancer Multidisciplinary Course, Johns Hopkins University, Baltimore, MD
- 6/06 Speaker, Optimizing Endocrine Therapy for Premenopausal Women with Breast Cancer Educational Session, ASCO Annual Meeting, Atlanta, GA
- 9/06 Keynote Speaker, ASCO/CAP HER2 Testing Guidelines, Plenary Lecture at College of American Pathologists Annual Meeting, San Diego, CA
- 11/06 Speaker, Risk Assessment and Prognostic Factors, NCCN symposium at San Johns Hopkins, Baltimore, MD
- 11/06 Speaker, Risk Assessment and Prognostic Markers/Update on Aromatase Inhibitors, Washington Adventist Breast Cancer Symposium, Bethesda, MD
- 6/07 Speaker, HER2 Testing in Clinical Practice, Clinical Problems in Oncology, Educational Session, ASCO Annual Meeting, Chicago, IL
- 6/07 Speaker, Ovarian Function Suppression and Being a Woman: How to Reconcile? 9th Milan Breast Cancer Conference, European Institute of Oncology, Milan, Italy
- 9/07 Speaker, HER2 Testing (General Session VI – HER2-Positive Breast Cancer), The 2007 Breast Cancer Symposium (co-sponsored by American Society of Breast Disease, the American Society of Breast Surgeons, ASCO, ASTRO - American Society for Radiation Oncology, National Consortium of Breast Centers, and Society of Surgical Oncology)
- 10/07 Speaker, Development & Approval of Trastuzumab, NCI/FDA/Industry Workshop on Development of Markers for Clinical Decision Making, Bethesda, MD
- 10/07 Speaker, Clinical Practice Implications of Oxford and St. Gallen, Sixth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy, New York, NY
- 1/08 Panelist, Breast Cancer Update Think Tank, Research to Practice, Miami, FL
- 1/08 Speaker, Latest Development in Cancer Treatment – Personalized Medicine, Coalition – Patient Advocate Training Workshop, Baltimore, MD
- 2/08 Visiting Faculty and Speaker, Controversies & Challenges in HER2 Testing, Dana Farber Cancer Institute, Boston, MA
- 4/08 Speaker, AACR – Forum, Approaches to Refractory Malignancies “Post-Preoperative, Systemic Therapy As a Research Tool for Refractory Breast Cancer” AACR Annual Meeting, San Diego, CA
- 4/08 Speaker, “Preoperative Systemic Therapy” and “Survivorship Panel” 4th Annual Multidisciplinary Breast Cancer Course, Johns Hopkins Medicine, Baltimore, MD
- 6/08 Speaker, HER2 Testing in Breast Cancer: Why Bother Testing? Educational Session
Speaker; How ASCO Guidelines can Improve Quality of Care. Educational Session
Speaker, Metastatic Breast Cancer Poster Discussion Scientific Session
ASCO Annual Meeting, Chicago, IL
- 6/08 Speaker, Adjuvant Chemotherapy for HER2-negative Breast Cancer
Speaker, Adjuvant Endocrine Therapy for Pre/Postmenopausal Women
Speaker, Predictive Markers for Adjuvant Treatment Selection
International Breast Cancer Symposium, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil
- 9/08 Speaker, Meet the Professor, Management of Early and Advanced Breast Cancer, Research to Practice, Washington, DC
- 10/08 Speaker, Are Genomic Assays Changing the Standard of Decision Making for Breast Cancer? Genomics and Decision Making for Breast Cancer, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
- 10/08 Speaker, HER2 Testing: What’s Real, What’s Not? 8th Lynn Sage Breast Cancer Symposium, Northwestern University, Chicago, IL
- 10/08 Speaker, Therapeutic Decisions in Early Stage Breast Cancer: The Power in Numbers or The Devil in the Details? Grand Rounds, Department of Oncology, Johns Hopkins, Baltimore, MD
- 3/09 Panel Speaker, Breast Cancer Survivorship, Maryland Chapter of the American College of Physicians, Baltimore, MD
- 6/09 Speaker, Multiplex Tissue Biomarkers For Risk Stratification in Early Stage Disease, Educational Session, ASCO Annual Meeting, Orlando, FL
- 6/09 Speaker, The Challenge of Treating Endocrine Responsive Disease: Overcoming Resistance & Choosing Additional Targets. 11th Milan Breast Cancer Conference, European Institute of Oncology, Milan, Italy
- 9/09 Panelist, Breast Predictive Factors: Test Interpretation Accuracy and Patient Treatment Implications, College of American Pathologists Annual Meeting, National Harbor, MD

- 12/09 Speaker, Developing Predictive Biomarkers in Breast Cancer: Challenges and Needs, Welch Center Grand Rounds, Department of Medicine, Johns Hopkins, Baltimore, MD
- 12/09 Panel Speaker, Breast Cancer Survivors: What Primary Care Providers Should Know, The Johns Hopkins/Harvard Medical School PriMed, Baltimore, MD
- 12/09 Speaker (w/ Claire Snyder), Cancer Survivorship, Fundamentals of Cancer: Cause to Cure, Johns Hopkins Kimmel Cancer Center
- 2/10 Speaker, Taking Care of Breast Cancer Survivors – A Shared-Care Model, 2010 American College of Physicians, Maryland Chapter, Annual Scientific Meeting, Ellicott City, MD
- 3/10 Speaker, Tumor Molecular Profiling in Clinical Practice
Speaker, Survivorship Care Management: Thoughts from an Oncologist and from an Internist
The Fifth Bi-Annual Johns Hopkins Breast Cancer Conference: Controversies in Management – a Multidisciplinary Perspective, Baltimore, MD
- 4/10 Speaker, Breast Predictive Factors: Test Interpretation Accuracy and Patient Treatment Implications, College of American Pathologists Training Session, ACP Headquarters, Northfield, IL
- 5/10 Speaker, Update on Adjuvant Therapy, Clinicopathologic and Molecular Predictors of Prognosis
Speaker, Update on Adjuvant Therapy, HER2-positive Disease
11th Annual Meeting, American Society of Breast Surgeons, Las Vegas, NV
- 6/10 Speaker, Loco-Regional/Adjuvant Poster Discussion Sessions, ASCO Annual Meeting, Chicago, IL
- 6/10 Spotlight Speaker, Androgen Receptors: Prognostic and Therapeutic Relevance, 12th Milan Breast Cancer Conference, European Institute of Oncology, Milan, Italy
- 9/10 Speaker, Predictive Biomarkers in Early Stage Breast Cancer, Grand Rounds, Department of Pathology, Johns Hopkins, Baltimore, MD
- 11/10 Speaker (w/ Claire Snyder), Cancer Survivorship, Fundamentals of Cancer: Cause to Cure, Johns Hopkins Kimmel Cancer Center
- 12/10 Panel Member, Clinical Case Presentations, 2010 San Antonio Breast Cancer Symposium
- 2/11 Invited Speaker, Targeted Therapies in Breast Cancer: The Challenges of Translating Clinical Research Findings to Daily Clinical Practice. Grand Rounds, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD
- 6/11 Invited Speaker, Endocrine Therapies for Postmenopausal Women.
Panel Participant, The Milan Breast Cancer Observatory: Innovation and care in the next 12 months. 13th Milan Breast Cancer Conference, European Institute of Oncology, Milan, Italy (upcoming)